| Diclofenac sodium 3% gel for the management of actinic keratosis: 10+ years of cumulative evidence of efficacy and safety. | |
| | |
MedLine Citation:
|
PMID: 22527428 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Background: Diclofenac sodium 3% gel (Solaraze®) gained US approval for the treatment of actinic keratosis (AK) more than 10 years ago. Since the publication of the pivotal phase 3 studies, numerous clinical studies have assessed use of this therapy in a variety of body areas, special populations, and novel combinations. Objective: To provide a comprehensive update on clinical data and research on the use of diclofenac sodium 3% gel in AK. Methods: Review of the literature. Results: Accumulating evidence from preclinical research supports that the proposed mechanism of diclofenac sodium 3% gel may include cyclo-oxgenase 2 (COX-2) inhibition, inhibition of angiogenesis, and induction of apoptosis. A literature review identified 17 publications (beyond the 2 pivotal studies) on the use of diclofenac sodium 3% gel for AK. A phase 4 open-label study reported that 58 percent of patients achieved complete clearance of target lesions at the 30-day post-treatment assessment; among patients who were evaluable at 1-year post-treatment, sustained long-term clearance of AK lesions was observed. Active comparator studies demonstrated comparable efficacy of diclofenac sodium 3% gel with 5-fluorouracil 5% and imiquimod 5%. Publications on the efficacy of diclofenac sodium 3% gel for AK of the lip report complete clearance rates comparable to those reported for other body areas. Diclofenac sodium 3% gel has also demonstrated efficacy for clearing AK lesions in immunosuppressed populations. Sequential use of diclofenac sodium 3% gel with cryosurgery or photodynamic therapy has been investigated and may emerge as a useful approach for some patients. Conclusions: Diclofenac sodium 3% gel has a unique proposed mechanism of action in AK that may involve COX-2 inhibition, inhibition of angiogenesis, and induction of apoptosis. In the past decade, numerous clinical studies have demonstrated this topical therapy to be effective and well tolerated for the treatment of AK. J Drugs Dermatol. 2012;11(5):600-608. |
| | |
Authors:
|
George M Martin; Eggert Stockfleth |
Related Documents
:
|
21145758 - Efficacy of intravenous levetiracetam as an add-on treatment in status epilepticus: a m... 21152928 - The management of periprosthetic leakage in the presence of supra-oesophageal reflux af... 21208198 - Buccal midazolam or rectal diazepam for treatment of residential adult patients with se... 17216828 - Utility of liver function tests after laparoscopic cholecystectomy. 17805018 - Results of femoral intramedullary nailing in patients who are obese versus those who ar... 14626718 - Median nerve function in patients undergoing carpal tunnel release: pre- and post-op ne... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of drugs in dermatology : JDD Volume: 11 ISSN: 1545-9616 ISO Abbreviation: J Drugs Dermatol Publication Date: 2012 May |
Date Detail:
|
Created Date: 2012-04-24 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101160020 Medline TA: J Drugs Dermatol Country: United States |
Other Details:
|
Languages: eng Pagination: 600-8 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Evaluation of the Chemopreventative Effects of ALA PDT in Patients With Multiple Actinic Keratoses a...
Next Document: Sarcoidosis as an adverse effect of tumor necrosis factor inhibitors.